TrialJournal for immunotherapy of cancer2023

First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817.

Neal E Ready et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.